Summary

Researchers at the Garvan Institute of Medical Research have discovered that the activity of a protein called CDK1 in breast cancers is linked to how they respond to a common therapy—an insight that could inform more personalized treatment approaches for patients. The study , published in Advanced Science , looked at estrogen receptor-positive (ER+) breast cancer—the most common type, fueled by the hormone estrogen. Many people with this cancer now receive drugs called CDK4/6 inhibitors alongside hormone therapy.

AI summaries can be wrong sometimes—always verify important details using the source article.